Key Highlights

● Atlassian closed fiscal 2026 with full-year Revenue of $6,572 million, up 26%, and subscription ARR of $6,606 million, up 23%, but guided fiscal 2027 to a slower roughly 13% total revenue growth pace.

● Omnicell beat estimates with second-quarter revenue of $312 million, up 7% year over year, yet shares fell roughly 11.7% after management widened its bookings range and disclosed $15 million in one-time Tariff refunds.

● Omada Health swung to GAAP profitability with second-quarter revenue of $87.835 million, up 43% year over year, and raised full-year guidance to $340 million in revenue while announcing a CEO transition effective January 1, 2027.

● EverQuote grew second-quarter revenue 25% to $195.1 million with $19.2 million in Net Income and a debt-free balance sheet, while Smith Micro Software posted just $4.3 million in quarterly revenue against a thin $2.8 million cash position.

Five very different Nasdaq names, a collaboration-software giant, a pharmacy-automation specialist, a connectivity micro-cap, a freshly public virtual-care company and an insurance marketplace, show how "software and AI services" has splintered into distinct risk-and-reward profiles heading into the mid-September Federal Reserve meeting.

One Label, Five Businesses That Barely Rhyme

"AI, software and technology services" has become a catch-all that hides more than it reveals. Underneath the label sit companies with wildly different revenue bases, margins and reasons to own them. Five Nasdaq-listed names that each reported results before mid-September 2026, Atlassian (NASDAQ: TEAM), Omnicell (NASDAQ: OMCL), Smith Micro Software (NASDAQ: SMSI), Omada Health (NASDAQ: OMDA) and EverQuote (NASDAQ: EVER), show how the theme actually behaves.

The distinction between fact and interpretation matters here. Reported figures below trace to company releases or SEC filings; anything about what the numbers mean is analysis, and anything about the future is forecast and inherently uncertain.

A Sector Priced Against a Fed That Will Not Blink

As of September 2026, the federal funds target range stands at 3.50%-3.75%, held unchanged at the July 2026 meeting for a fifth straight decision, with three FOMC members dissenting in favor of a 25-basis-point hike, according to a summary of the decision. The next FOMC meeting is scheduled for September 15-16, 2026.

That backdrop shapes the whole theme. Software valuations, especially for unprofitable or richly multiple-rated growth names, are sensitive to the discount rate applied to distant cash flows. A Fed that is holding, with hawkish dissents rather than dovish ones, offers no obvious multiple tailwind. It puts the burden back on operating performance: revenue growth, Margin expansion and, increasingly, evidence that artificial-intelligence features convert into paid usage rather than cost.

A meeting landing one day after publication is a genuine near-term catalyst for rate-sensitive software, though its direction is unknowable in advance. The September decision and the accompanying projections are the immediate macro variable, before returning to company-specific execution as the durable driver.

Atlassian (NASDAQ:TEAM): Cloud Momentum Meets a Slower Guidance Bar

Atlassian Corporation reported fourth-quarter and full-year fiscal 2026 results for the period ended June 30, 2026. Q4 revenue was $1,766 million, up 28% year over year, with cloud revenue of $1,213 million, up 31%. Q4 GAAP Operating Income was $211 million, a 12% margin, and diluted EPS $0.55; non-GAAP diluted EPS was $1.87. For the full year, revenue reached $6,572 million, up 26%, with a GAAP net loss of $0.21 per share and non-GAAP net income of $1,526 million, EPS $5.85. Subscription annual Recurring Revenue closed at $6,606 million, up 23%. For fiscal 2027, management guided to subscription ARR growth of roughly 18%, total revenue growth of about 13% and cloud revenue growth of around 25.5%.

On the product side, Atlassian said its Rovo AI tooling added HIPAA compliance and advanced admin controls, and cited more than one million monthly active users tied to its MCP server and Teamwork Graph.

The signal is a company still growing cloud in the low-30s while flagging a step-down in the fiscal 2027 growth bar. The open question is whether agentic AI features become a monetized upsell rather than a retention feature; that debate, not the June quarter, likely drives the stock into 2027.

Omnicell (NASDAQ:OMCL): A Tariff-Aided Beat and a Wider Bookings Range

Omnicell, Inc. reported second-quarter 2026 results for the period ended June 30, 2026. Total revenue was $312 million, up 7% year over year, split between product revenue of $175.1 million and service revenue of $137.1 million. GAAP net income was $0.52 per diluted share and non-GAAP diluted EPS was $0.94. The quarter included $15 million in refunds for previously paid IEEPA tariffs. Full-year 2026 guidance was set at 1.245 billion in revenue, product bookings of 560 million, non-GAAP EBITDA of 185 million and non-GAAP EPS of 2.30.

According to an earnings-data aggregator, Omnicell shares fell roughly 11.7% to $36.56 following the report; management said the widened bookings range reflected unpredictable timing of customer decisions rather than cancellations, and guided year-end ARR to 680 million versus a $636 million 2025 baseline.

A headline beat undercut by a one-time tariff benefit and a conspicuously wide bookings range explains the negative reaction. The pharmacy-automation thesis remains intact, but the recurring-revenue ramp is proving slower than the market wanted. Bookings conversion over the next two quarters is the metric that decides whether the ARR target holds.

Smith Micro Software (NASDAQ:SMSI): A Micro-Cap Fighting for Its Second Act

Smith Micro Software, Inc. reported second-quarter 2026 revenue of $4.3 million for the period ended June 30, 2026, down 2% from $4.4 million a year earlier; first-half revenue was $8.6 million versus $9.0 million. Family Safety revenue was $3.5 million and CommSuite was $826,000. Gross margin was 81.3%. The GAAP net loss was $0.52 per share and the non-GAAP net loss was $0.19 per share. Cash and equivalents stood at $2.8 million at quarter-end. For Q3 2026, the company guided to revenue of 5.4 million and gross margin of 81%-83%.

Management highlighted the launch of SafePath Connect and a push into SDK and API deployment channels beyond traditional carrier white-label arrangements.

This is a connectivity-software micro-cap whose story rests on diversifying beyond a concentrated carrier base while defending a thin cash position. The high gross margin is real, but at roughly $4 million in quarterly revenue and $2.8 million in cash, the Balance Sheet leaves little room for error. The sequential jump implied by Q3 guidance is the near-term test; sustained sequential growth, not a single quarter, is what would change the narrative. Micro-caps at this scale carry elevated Liquidity and dilution risk.

Omada Health (NASDAQ:OMDA): A Recent IPO Turning Profitable Amid a CEO Handoff

Omada Health, Inc. priced its IPO at $19 per share in June 2025 and began trading on Nasdaq shortly after. For the second quarter of 2026, ended June 30, 2026, Omada reported total revenue of $87.835 million, up 43% year over year, with total members up 45%. GAAP net income was $5.294 million and adjusted EBITDA was $10.786 million; gross margin was 73%, or 74% non-GAAP. Full-year 2026 guidance was raised to 340 million in revenue and 27 million in adjusted EBITDA. Alongside results, Omada announced that co-founder Sean Duffy will become Founder and Executive Chair effective January 1, 2027, with President Wei-Li Shao becoming CEO.

For a digital-health name barely a year public, swinging to GAAP profitability while growing revenue in the 40s is a notable inflection, and the GLP-1 care programs give it exposure to one of health tech's fastest-moving Demand pockets. A Leadership transition at a young public company is a watch item, though; continuity of commercial momentum through the handoff is the variable to monitor, and reimbursement and competitive dynamics in virtual care remain unsettled.

EverQuote (NASDAQ:EVER): An Insurance Marketplace Compounding on Carrier Demand

EverQuote, Inc. reported second-quarter 2026 revenue of $195.1 million, up 25% year over year, for the period ended June 30, 2026. Net income was $19.2 million and adjusted EBITDA was $30.1 million, up 37%. Variable Marketing dollars were $56.9 million, and the company held $192.3 million in cash with no debt. For the third quarter of 2026, EverQuote guided to revenue of 208.0 million, variable marketing dollars of 59.0 million and adjusted EBITDA of 31.0 million. Management attributed part of the momentum to AI-driven improvements in its marketplace.

EverQuote is the cleanest "profitable growth" profile in this group: double-digit revenue growth, expanding adjusted EBITDA, GAAP net income and a debt-free balance sheet. Its fortunes are tied to auto-insurance carriers' willingness to spend on customer acquisition, which has been a tailwind. That same carrier dependency is the risk, since a pullback in insurer marketing budgets would hit the model quickly. The Q3 guidance implies continued growth, but the sequential adjusted-EBITDA range is roughly flat, which is worth watching.

What Investors Should Watch

The near-term macro pivot is the September 15-16 FOMC meeting and its guidance for the rest of 2026. Beyond that, each name has its own tell: Atlassian's AI monetization and the fiscal 2027 growth step-down; Omnicell's bookings conversion and ARR trajectory; Smith Micro's ability to string together sequential growth off a thin cash base; Omada's execution through a CEO transition; and EverQuote's dependence on carrier Advertising demand. The unifying test across all five is whether growth and margins can carry valuations without help from falling rates.

Selectivity Beats a Blanket Bet on the Label

These five stocks share a Nasdaq listing and a loose "software and AI services" label, but they are not one trade. They span a profitable large-cap, a hardware-plus-software healthcare specialist, a struggling micro-cap, a newly profitable digital-health IPO and a cash-generative marketplace. That dispersion is the point: in September 2026, the theme rewards selectivity over blanket exposure, and every figure here is worth checking against primary filings before drawing conclusions, given how differently sized the risk profiles on display really are.